GlaxoSmithKline
NEWS
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
The approval was specifically for patients with recurrent or advanced endometrial cancer who had progressed on or after previous treatment with platinum-based chemotherapy and whose cancers have a dMMR genetic anomaly.
GlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
In a stunning fall from grace playing out this week, former Operation Warp Speed vaccine czar, Dr. Moncef Slaoui, issued a statement Thursday morning, as news emerged that he has resigned from additional biotech posts.
Moncef Slaoui was fired as chairman of the board of directors of Galvani Bioelectronics following allegations of sexual harassment and inappropriate conduct.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
Multiple pharmaceutical companies struck large licensing deals with one another this week. Here’s a look.
Topline data from Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.
JOBS
IN THE PRESS